Targeting LSD1/NuRD complex with available epigenetic drugs (LSD1i) to reactivate the expression of pro-apoptotic BIM protein could offer better clinic outcomes for ETP-ALL patients. Here, BCL2L11 is linked to acute lymphoblastic leukemia.